Tag Archive | "pharma"

Array Biopharma regains binimetinib from Novartis

Tags: , , ,


Array BioPharma has reached a definitive agreement with Novartis to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials Read the full story

Allena Pharmaceuticals gains series B financing for $25 million

Tags: ,


Allena Pharmaceuticals announced the succesful completion of a $25 million Series B financing Read the full story

Vaccinex and Janssen in cancer collaboration

Tags: , ,


Vaccinex has entered into a research collaboration with Janssen Research & Developmentfor the creation of novel anti-cancer agents Read the full story

Naurex secures series C financing for $80 million

Tags: ,


Naurex announced the completion of an $80 million Series C financing round Read the full story

Astellas and Janssen terminate ASP015K deal

Tags: , , , , ,


Astellas Pharma announced that its license agreement with Janssen Biotech, to develop and commercialize ASP015K, oral Janus Kinase (JAK) inhibitor, will end Read the full story

Atreca and Janssen in Immune Repertoire Capture technology pact

Tags: , , , ,


Atreca has entered into a strategic collaboration with Janssen Biotech in which the companies will apply Atreca’s Immune Repertoire Capture technology to autoimmune disease Read the full story

Seres banks $48 million series C financing

Tags: ,


Seres Health has closed its Series C round with $48 million in new investment Read the full story

Mylan and Gilead in tenofovir alafenamide licensing pact

Tags: , , , , ,


Mylan has entered into an agreement with Gilead Sciences under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide Read the full story

PMV Pharma secures $30 million series A financing

Tags: ,


PMV Pharmaceuticals announced the completion of a $30 million Series A financing Read the full story

Alimera Sciences gains $50 million commitment from Deerfield

Tags: ,


Alimera Sciences has entered into a Securities Purchase Agreement with Deerfield Management and certain of its affiliates pursuant to which Alimera will issue shares of preferred stock to Deerfield with an aggregate purchase price of approximately $50.0 million upon the satisfaction of certain closing conditions Read the full story